Legis Daily

Lower Costs, More Cures Act of 2021

USA117th CongressS-2164| Senate 
| Updated: 6/22/2021
Mike Crapo

Mike Crapo

Republican Senator

Idaho

Cosponsors (8)
Joni Ernst (Republican)Roger Marshall (Republican)Thomas Tillis (Republican)James E. Risch (Republican)Tim Scott (Republican)Steve Daines (Republican)John Hoeven (Republican)Richard Burr (Republican)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Lower Costs, More Cures Act of 2021 This bill establishes and modifies several programs and requirements to address prescription drug prices, particularly in relation to Medicare and Medicaid. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; caps annual out-of-pocket spending under the Medicare prescription drug benefit; allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; establishes requirements under the Medicaid Drug Rebate Program for certain gene therapies for which prices are indexed to achieved outcomes; and establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-3129
Lower Costs, More Cures Act of 2019
Jun 22, 2021
Introduced in Senate
Jun 22, 2021
Read twice and referred to the Committee on Finance.
Oct 19, 2021

Latest Companion Bill Action

HR 117-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
  • Bill from Previous Congress

    S 116-3129
    Lower Costs, More Cures Act of 2019


  • June 22, 2021
    Introduced in Senate


  • June 22, 2021
    Read twice and referred to the Committee on Finance.


  • October 19, 2021

    Latest Companion Bill Action

    HR 117-19
    Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Health

Related Bills

  • HR 117-4417: Capping Drug Costs for Seniors Act of 2021
  • HR 117-3682: Improving Transparency to Lower Drug Costs Act of 2021
  • S 117-2815: Seniors Saving on Insulin Act
  • S 117-1287: REFUND Act of 2021
Business recordsCivil actions and liabilityCongressional oversightConsumer affairsDepartment of Health and Human ServicesDigestive and metabolic diseasesDrug safety, medical device, and laboratory regulationDrug therapyExecutive agency funding and structureFood and Drug Administration (FDA)Fraud offenses and financial crimesGeneticsGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth personnelHealth promotion and preventive careHealth technology, devices, suppliesHome and outpatient careInflation and pricesManufacturingMarketing and advertisingMedicaidMedical researchMedicareOffice of the U.S. Trade RepresentativePrescription drugsProduct development and innovationPublic participation and lobbyingTrade agreements and negotiations

Lower Costs, More Cures Act of 2021

USA117th CongressS-2164| Senate 
| Updated: 6/22/2021
Lower Costs, More Cures Act of 2021 This bill establishes and modifies several programs and requirements to address prescription drug prices, particularly in relation to Medicare and Medicaid. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; caps annual out-of-pocket spending under the Medicare prescription drug benefit; allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; establishes requirements under the Medicaid Drug Rebate Program for certain gene therapies for which prices are indexed to achieved outcomes; and establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-3129
Lower Costs, More Cures Act of 2019
Jun 22, 2021
Introduced in Senate
Jun 22, 2021
Read twice and referred to the Committee on Finance.
Oct 19, 2021

Latest Companion Bill Action

HR 117-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
  • Bill from Previous Congress

    S 116-3129
    Lower Costs, More Cures Act of 2019


  • June 22, 2021
    Introduced in Senate


  • June 22, 2021
    Read twice and referred to the Committee on Finance.


  • October 19, 2021

    Latest Companion Bill Action

    HR 117-19
    Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Mike Crapo

Mike Crapo

Republican Senator

Idaho

Cosponsors (8)
Joni Ernst (Republican)Roger Marshall (Republican)Thomas Tillis (Republican)James E. Risch (Republican)Tim Scott (Republican)Steve Daines (Republican)John Hoeven (Republican)Richard Burr (Republican)

Finance Committee

Health

Related Bills

  • HR 117-4417: Capping Drug Costs for Seniors Act of 2021
  • HR 117-3682: Improving Transparency to Lower Drug Costs Act of 2021
  • S 117-2815: Seniors Saving on Insulin Act
  • S 117-1287: REFUND Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCivil actions and liabilityCongressional oversightConsumer affairsDepartment of Health and Human ServicesDigestive and metabolic diseasesDrug safety, medical device, and laboratory regulationDrug therapyExecutive agency funding and structureFood and Drug Administration (FDA)Fraud offenses and financial crimesGeneticsGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth personnelHealth promotion and preventive careHealth technology, devices, suppliesHome and outpatient careInflation and pricesManufacturingMarketing and advertisingMedicaidMedical researchMedicareOffice of the U.S. Trade RepresentativePrescription drugsProduct development and innovationPublic participation and lobbyingTrade agreements and negotiations